GEN-MKT-18-7897-A
Apr 13, 2021 | Blogs, Environmental / Industrial | 0 comments
Read time: 4 minutes
Introduction to cannabis: analysis
Cannabis is a broad umbrella of classification that includes both hemp and marijuana. Check out a recent blog that lays out the definitions. This blog will focus on the common criteria we look at when conducting cannabis testing, including potency, pesticides and mycotoxins.
Potency: how do you test for it?
Based on individual state regulatory requirements in the US, the potency of commercial cannabis products must be reported. The percentage of THC is printed on cannabis product labels after being certified by a licensed cannabis testing facility. The methodology for obtaining cannabis potency values can vary based on the analytical technique and instrumentation used, which gives testing facilities options for customizing or streamlining their workflows. While marijuana potency testing can vary, hemp analysis has to be accurate, or the crop is considered cannabis and subject to federal confiscation and fines. The US, however, lacks standardized methods to assess products for potency and safety. That’s a big problem for the labs that are tasked with doing the testing. There have been many challenges in the uniformity of potency results across testing sites. Some manufacturers will go to the lab that gives them the highest potency results. Pesticides, mycotoxins and terpenes, oh my!
As states in the US struggle to set standards for testing, both consumers and retailers are becoming increasingly discerning. Because of the variability and diversity of the matrix composition of samples—which can include cannabinoids, terpenes, sugars, fatty acids and more—analyzing cannabis and hemp for pesticides can be daunting. This is especially true for high-throughput cannabis and hemp residue testing. If you want to learn more about this topic, check out our tips and tricks for pesticide residue analysis in cannabis. Stay tuned for more blogs and information on the analysis of cannabis and hemp.
RUO-MKT-18-13032-A
As therapeutic pipelines continue to diversify, bioanalysis is being asked to do more than ever before. From small molecules to complex biologics, today’s scientists must generate high‑quality, reliable data across a growing range of molecule types and workflows, often under increasing time pressure.
Regulated laboratories are evolving faster than ever. New analytical modalities, higher sample throughput, increasing regulatory scrutiny, and leaner teams are reshaping how work gets done. At the same time, expectations for data integrity, standardization, and operational efficiency continue to increase complexity and/or scope. In this environment, LC-MS software is no longer simply an instrument control platform—it has become a critical part of a laboratory’s quality management system. The question is no longer whether your lab has changed, but whether your software has evolved to support the way regulated labs operate today, and if they are ready and able to meet the demands, they will face tomorrow.
Analyst software has long been a trusted foundation in regulated LC-MS laboratories—and for many, it still performs reliably today. But regulated environments are evolving faster than ever. As labs transition to Windows 11, strengthen cybersecurity policies, modernize IT infrastructure, and prepare for future compliance expectations, software decisions are no longer just about what works today—they’re about managing tomorrow’s risk. Analyst will not be supported on Windows 11. While some labs may continue operating in unsupported environments temporarily, the bigger question is: when that risk becomes reality, will your lab be reacting under pressure—or executing a planned mitigation strategy with confidence?
Posted by
You must be logged in to post a comment.
Share this post with your network